New treatment for common inherited kidney disease found

A new technique which involves targeting tiny blood and lymphatic vessels inside the kidneys may slow the progression of a common inherited kidney disease, researchers have found.
These treatments can help alleviate some of the symptoms of PKD but they can't currently cure the condition, according to researchers based at the UCL Institute of Child Health (ICH), the research partner of Great Ormond Street Hospital.
Published in the Journal of the American Society of Nephrology, the treatment, which involves targeting tiny blood and lymphatic vessels inside the kidneys, is shown to improve renal function and slow progression of disease in mice.

Polycystic kidney disease (PKD) is a genetic disorder where fluid filled cysts grow in kidneys and destroy normal renal tissue. It is the world's most common inherited kidney disease affecting between 1 in 400 and 1 in 1000 people worldwide - around 12.5 million individuals.
A rarer form of the disease, which occurs in about one in every 20,000 live births in the UK, leads to a third of these babies dying before or just after birth.
Treatment for the condition has traditionally targeted proteins which are thought to play a role in causing the condition and are located in hair-like structures and tissue that line the inside of cysts.

Researchers have now discovered that the blood and lymphatic system surrounding cysts may also be important in the development of the condition and could be a new target for treating the disease.

By looking at mouse models of both the common and rarer form of the disease, the team noticed that tiny blood vessels surrounding the cysts were altered very early in cyst development.
Therefore, they treated the mice with a potent 'growth factor' protein called VEGFC, and found that patterns of blood vessels normalised and the function of the kidneys improved.
In the mice with the rare form of the condition, it also led to a modest but significant increase in lifespan.

"With further testing, treatments that target blood vessels surrounding the kidney cysts, perhaps in combination with currently used drugs, may prove to be beneficial for patients with polycystic kidney disease," David Long, lead researcher and Principal Research Associate at the ICH, said.
Adrian Woolf, Professor of Paediatric Science at the University of Manchester and co-author of the study, added that if we could target these blood vessels early in the development of the condition it could potentially lead to much better outcomes for patients.
"By identifying a treatment plan that can prevent further deterioration of kidney function in patients with this particular disease, our researchers have given fresh hope to thousands of people in the UK with this kidney condition," Elaine Davies, Research Director at Kidney Research UK and Richard Trompeter, Chairman of Kids Kidney Research, said.